Leerink Swann maintained an Outperform rating on Rigel Pharmaceuticals (NASDAQ: RIGL) and lowered its price target to $5.00 (from $7.00) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE